Copyright Reports & Markets. All rights reserved.

USA Angiogenesis Modulators Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Angiogenesis Modulators Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Angiogenesis Inhibitors Market Performance (Volume)
      • 2.1.2 Angiogenesis Stimulators Market Performance (Volume)
      • 2.1.3 Angiogenin Market Performance (Volume)
      • 2.1.4 Others Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Angiogenesis Inhibitors Market Performance (Value)
      • 2.1.2 Angiogenesis Stimulators Market Performance (Value)
      • 2.1.3 Angiogenin Market Performance (Value)
      • 2.1.4 Others Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Breast Cancer Market Performance (Volume)
      • 3.1.2 Colorectal Cancer Market Performance (Volume)
      • 3.1.3 Lung Cancer Market Performance (Volume)
      • 3.1.4 Prostate Cancer Market Performance (Volume)
      • 3.1.5 Others Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Celgene Corporation (USA)
      • 4.1.1 Celgene Corporation (USA) Profiles
      • 4.1.2 Celgene Corporation (USA) Product Information
      • 4.1.3 Celgene Corporation (USA) Angiogenesis Modulators Business Performance
      • 4.1.4 Celgene Corporation (USA) Angiogenesis Modulators Business Development and Market Status
    • 4.2 Eisai Co., Ltd. (Japan)
      • 4.2.1 Eisai Co., Ltd. (Japan) Profiles
      • 4.2.2 Eisai Co., Ltd. (Japan) Product Information
      • 4.2.3 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Business Performance
      • 4.2.4 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Business Development and Market Status
    • 4.3 Amgen, Inc. (USA)
      • 4.3.1 Amgen, Inc. (USA) Profiles
      • 4.3.2 Amgen, Inc. (USA) Product Information
      • 4.3.3 Amgen, Inc. (USA) Angiogenesis Modulators Business Performance
      • 4.3.4 Amgen, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
    • 4.4 Genentech, Inc. (USA)
      • 4.4.1 Genentech, Inc. (USA) Profiles
      • 4.4.2 Genentech, Inc. (USA) Product Information
      • 4.4.3 Genentech, Inc. (USA) Angiogenesis Modulators Business Performance
      • 4.4.4 Genentech, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
    • 4.5 GlaxoSmithKline plc (UK)
      • 4.5.1 GlaxoSmithKline plc (UK) Profiles
      • 4.5.2 GlaxoSmithKline plc (UK) Product Information
      • 4.5.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Business Performance
      • 4.5.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Business Development and Market Status
    • 4.6 Bayer Pharma AG (Germany)
      • 4.6.1 Bayer Pharma AG (Germany) Profiles
      • 4.6.2 Bayer Pharma AG (Germany) Product Information
      • 4.6.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Business Performance
      • 4.6.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Business Development and Market Status
    • 4.7 Bionomics Ltd. (Australia)
      • 4.7.1 Bionomics Ltd. (Australia) Profiles
      • 4.7.2 Bionomics Ltd. (Australia) Product Information
      • 4.7.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Business Performance
      • 4.7.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Business Development and Market Status
    • 4.8 CASI Pharmaceuticals, Inc. (USA)
      • 4.8.1 CASI Pharmaceuticals, Inc. (USA) Profiles
      • 4.8.2 CASI Pharmaceuticals, Inc. (USA) Product Information
      • 4.8.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Business Performance
      • 4.8.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
    • 4.9 AstraZeneca plc (UK)
      • 4.9.1 AstraZeneca plc (UK) Profiles
      • 4.9.2 AstraZeneca plc (UK) Product Information
      • 4.9.3 AstraZeneca plc (UK) Angiogenesis Modulators Business Performance
      • 4.9.4 AstraZeneca plc (UK) Angiogenesis Modulators Business Development and Market Status
    • 4.10 Eli Lilly and Company (USA)
      • 4.10.1 Eli Lilly and Company (USA) Profiles
      • 4.10.2 Eli Lilly and Company (USA) Product Information
      • 4.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Business Performance
      • 4.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Business Development and Market Status
    • 4.11 F.Hoffmann-La Roche AG (Switzerland)

    5 Market Performance for Manufacturers

    • 5.1 USA Angiogenesis Modulators Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 USA Angiogenesis Modulators Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 USA Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 USA Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Northeast Market Performance for Manufacturers
      • 6.1.1 Northeast Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Northeast Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Northeast Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Northeast Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Midwest Market Performance for Manufacturers
      • 6.2.1 Midwest Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Midwest Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Midwest Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Midwest Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Market Performance for Manufacturers
      • 6.3.1 South Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 West Market Performance for Manufacturers
      • 6.4.1 West Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 West Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 West Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 West Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration

    7 USA Angiogenesis Modulators Market Performance (Sales Point)

    • 7.1 USA Angiogenesis Modulators Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 USA Angiogenesis Modulators Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 USA Angiogenesis Modulators Price (USD/Unit) by Regions 2013-2018
    • 7.4 USA Angiogenesis Modulators Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 USA Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Northeast Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Midwest Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 West Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Breast Cancer Industry
    • 11.2 Colorectal Cancer Industry
    • 11.3 Lung Cancer Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 USA Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 USA Angiogenesis Modulators Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Northeast Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Midwest Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 West Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Angiogenesis Inhibitors Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Angiogenesis Stimulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Angiogenin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Breast Cancer Sales and and Growth Rate 2019-2024
      • 12.4.3 Colorectal Cancer Sales and and Growth Rate 2019-2024
      • 12.4.4 Lung Cancer Sales and and Growth Rate 2019-2024
      • 12.4.5 Prostate Cancer Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 USA Angiogenesis Modulators Price (USD/Unit) Trend 2019-2024
      • 12.5.2 USA Angiogenesis Modulators Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split USA into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Angiogenesis Modulators for these regions, from 2012 to 2023 (forecast), including
    Northeast
    Midwest
    South
    West

    USA Angiogenesis Modulators market competition by top manufacturers/players, with Angiogenesis Modulators sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Celgene Corporation (USA)
    Eisai Co., Ltd. (Japan)
    Amgen, Inc. (USA)
    Genentech, Inc. (USA)
    GlaxoSmithKline plc (UK)
    Bayer Pharma AG (Germany)
    Bionomics Ltd. (Australia)
    CASI Pharmaceuticals, Inc. (USA)
    AstraZeneca plc (UK)
    Eli Lilly and Company (USA)
    F.Hoffmann-La Roche AG (Switzerland)

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Angiogenesis Inhibitors
    Angiogenesis Stimulators
    Angiogenin
    Others

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Angiogenesis Modulators for each application, including
    Breast Cancer
    Colorectal Cancer
    Lung Cancer
    Prostate Cancer
    Others

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now